The Latest Breaking News from Grail

Cancer Blood Test Galleri Nears FDA Decision as Screening Researcher Warns Its Main Trial Missed Its Goal

Galleri cancer blood test awaits an FDA decision as a screening researcher says its main trial fell short. See the $949 cost, coverage, and what to know.

Medical Daily · Oct 8

FDA Panel votes in favor of a $949 Cancer detecting blood test, but is Galleri ready for approval?

Cancer cells can leave tiny fragments of DNA in the bloodstream. According to USA Today, Galleri studies chemical patterns found on these fragments. A machine-learning system then analyzes the results for signals that could point to cancer.

The Economic Times · Sep 25

FDA Advisers Back Multi-Cancer Blood Test for Adults 50 and Up but Split 6 to 4 on Effectiveness

An FDA panel voted 7-2 that the Galleri cancer blood test's benefits outweigh its risks, but split 6-4 on effectiveness. What it means for adults 50 and older.

Medical Daily · Sep 24

One Blood Test Could Detect 50 Cancers at Once — the FDA Decision That Could Change Screening Forever

GRAIL's Galleri blood test may detect up to 50 cancers in one vial. The FDA is reviewing a premarket approval application submitted in January 2026. Here's what you need to know.

Medical Daily · Jun 25

GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint

GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its lar

MarketBeat · Jun 1

Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim

Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnoses

The Guardian - UK · May 30

New blood test ‘offers genuine hope’ it can detect deadly cancers before symptoms appear

The test is ‘feasible at scale’ on the NHS, say researchers

The Independent UK · May 30

Galleri blood test ‘feasible at scale’ on NHS, say experts

The NHS-Galleri trial is exploring how well the blood test works within the health service, alongside screening, to pick up cancer cases earlier.

Evening Standard · May 30

GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead

GRAIL (NASDAQ:GRAL) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company’s CFO, at a Bank of America event. Aaron said t

MarketBeat · May 17

I was asked if there was an ‘everything’ test for cancer. Despite bold claims, no such thing exists

For oncologists like me, it would be a different world if we could accurately detect cancer before it metastasised and reassure patients that early intervention saved lives

The Guardian - AU · Mar 24